Orca Bio key facts
as of Oct 2026- Developer of cell therapy products designed to replace patients' diseased blood and immune systems with healthy ones.
- Orca Bio is valued at approximately $1.2B as of Oct 2026 (last reported valuation).
- It has raised $625.0M; the latest was Later Stage VC ($250.0M) in Jan 2026.
- Notable investors include Lightspeed Venture Partners, 8VC, StartX (US), Felicis, DCVC — 19 tracked in total.
- Status: Privately Held (backing).
Orca Bio's last reported valuation, Jun 2020. Nothing priced has surfaced since.
- ·The complete investor list: 19 names
- ·Watch Orca Bio: the Monday email on marks, rounds and moves
Orca Bio funding rounds
No funding rounds for Orca Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Orca Bio
19+Membership and data by Private Market View
Orca Bio valuation
Orca Bio's last reported valuation was $1.2 billion in Jun 2020. No priced round, secondary trade or fund mark has surfaced since.
Orca Bio investors
19 investors are on record for Orca Bio, including Lightspeed Venture Partners, 8VC, StartX (US) and Felicis. By type, the record holds 8 venture capital firms and 1 family office.
About Orca Bio
Developer of cell therapy products designed to replace patients' diseased blood and immune systems with healthy ones. The company specializes in the research and development of novel cell therapies that help to transform all aspects of bone marrow transplant and create a life-saving platform for many diseases, enabling healthcare professionals to efficiently treat their patients.
- Sector
- Healthcare
- HQ
- Menlo Park, CA, United States
- Founded
- 2015
- Employees
- 297
- Website
- orcabio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.